REaCT: REthinking Clinical Trials

REaCT-EF

REaCT-EF	Frequency of cardiac monitoring (echocardiogram or MUGA scan every 4 months vs. every 3 months) for patients with early stage breast cancer. Principal Investigator(s): Dr. John Hilton
ClinicalTrials.gov: NCT02696707
Several large adjuvant trastuzumab trials have demonstrated improved overall survival in patients with early stage breast cancer, with a 33% decrease in risk of death. However, retrospective analyses of patient outcomes in these trials have demonstrated increased risk of cardiotoxicity (i.e. damage to the heart) in a small number of patients. During a patient’s trastuzumab treatment, some oncologists order cardiac scans every 3 months while others order every 4 months. At this time, it is not known which standard monitoring schedule is optimal. This study has met accrual and follow-up is ongoing.
Sites: The Ottawa Hospital Thunder Bay Regional Health Sciences Centre
Tags: Early stage Breast Cancer
Publications: Clinical Trials results A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Dent et al, 2021. PMID: 34940066